TLR7 TLR8 Agonists Modulating Immune Response Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies face challenges in effectively activating the immune system to induce robust and specific immune responses, particularly in enhancing Type I interferon production and adaptive immunity, while minimizing inflammatory cytokine induction.
Innovation Solution
Development of specific TLR7 and TLR8 agonists, such as imidazopyridine and 1-alkyl-1H-benzimidazol-2-amine derivatives, which act as small-molecule immunostimulants to induce potent Type I interferon and proinflammatory cytokine responses, serving as potential vaccine adjuvants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR ligands are used to activate the immune system, then Type I interferon production and adaptive immunity are enhanced, but inflammatory cytokine induction increases
Solution Approach 1:
The patent applies local quality by designing TLR ligands with specific structural modifications that create different functional zones within the molecule. The core structure maintains immunostimulatory activity while specific substituent groups (such as fluorine atoms at particular positions, specific alkyl chains, or aromatic rings) are introduced to modulate the inflammatory response profile. This allows different parts of the molecule to have differentiated functions: one region activates TLR for immune enhancement while another region controls inflammatory cytokine production
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the TLR ligand structure, including substituting hydrogen atoms with fluorine at specific positions, modifying alkyl chain lengths, changing aromatic ring substituents, and adjusting molecular weight. These parameter modifications result in compounds that maintain or enhance Type I interferon production while attenuating inflammatory cytokine induction, as demonstrated by the structure-activity relationships established in the patent
2Productivity
If broad-spectrum TLR agonists are used, then multiple immune pathways are activated, but specificity of immune response decreases
Solution Approach 1:
The patent applies segmentation by dividing the TLR agonist market into specific subcategories based on TLR subtype selectivity. The compounds are designed to target specific TLR subtypes (TLR7, TLR8, or TLR9) rather than activating all TLRs broadly. This segmentation is achieved through structural features that confer selectivity, such as specific ring structures and substituent patterns that match particular TLR binding pockets, thereby maintaining high immune activation potency while achieving response specificity
Solution Approach 2:
The patent inverts the conventional approach by designing ligands that are selective for specific TLR subtypes rather than broad-spectrum activators. Instead of creating a single compound that activates all TLRs, the invention develops series of compounds each optimized for a particular TLR subtype, reversing the traditional strategy of broad activation and achieving specificity through targeted design
Data Source
AI summary
Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae. Examples of the compounds can be reviewed in Table 1 and Table A1 for activates.